Maravai Lifesciences Holdings (MRVI) said Monday that it completed the acquisition of Officinae Bio's DNA and RNA business.
The company said the deal combines Officinae Bio's AI-driven mRNA design platforms with Maravai's and TriLink BioTechnologies' expertise in drug substance manufacturing, offering customers advanced technologies designed to achieve efficient progression from mRNA sequence optimization to clinical testing and commercial manufacturing.
Davide De Lucrezia, chief executive officer of Officinae Bio, will continue to lead the Officinae Bio team, now part of Maravai's Nucleic Acid Production segment, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.